Payment overview · 2025
General Payments
$1,754.08
80 reported records · 6 companies
Healthcare provider profile · identity verified
Xiaorong He, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELMHURST, NY · NPI 1962422972
Verified facts
What the public records show
CMS Open Payments records show Xiaorong He, M.D. received $1,754.08 in general payments during 2025 across 80 reported records.
ABBVIE INC. accounted for 34.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 622 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $600.45 | 34.2% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $438.77 | 25.0% | 19 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $276.84 | 15.8% | 12 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $255.07 | 14.5% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $130.37 | 7.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $52.58 | 3.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,744.08 | 79 |
| Education | $10.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $500.62 | 23 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $372.35 | 15 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $255.07 | 11 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $199.07 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.87 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.87 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $78.06 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $52.58 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $52.58 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.02 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 622 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 220 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 102 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 253 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
622 | 80 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
102 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
100 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
220 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
128 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
129 | 30 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
211 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
253 | 126 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 2353 | 243 |
| Losartan Potassium | Losartan Potassium | 1875 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 1784 | 211 |
| Omeprazole | Omeprazole | 1402 | 222 |
| Simvastatin | Simvastatin | 1284 | 154 |
| Gabapentin | Gabapentin | 1187 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1125 | 153 |
| Metformin Hcl Er | Metformin Hcl | 1011 | 123 |
| Trazodone Hcl | Trazodone Hcl | 931 | 143 |
| Famotidine | Famotidine | 923 | 110 |
| Ursodiol | Ursodiol | 910 | 94 |
| Raloxifene Hcl | Raloxifene Hcl | 863 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 792 | 95 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 777 | 179 |
| Ammonium Lactate | Ammonium Lactate | 716 | 151 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 684 | 83 |
| Meclizine Hcl | Meclizine Hcl | 680 | 154 |
| Diclofenac Epolamine | Diclofenac Epolamine | 664 | 93 |
| Halobetasol Propionate | Halobetasol Propionate | 631 | 152 |
| Creon | Lipase/Protease/Amylase | 622 | 80 |
| Diclofenac Sodium | Diclofenac Sodium | 607 | 178 |
| Meloxicam | Meloxicam | 594 | 168 |
| Donepezil Hcl | Donepezil Hcl | 582 | 87 |
| Myrbetriq | Mirabegron | 556 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 536 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 500 | 62 |
| Alendronate Sodium | Alendronate Sodium | 481 | 66 |
| Celecoxib | Celecoxib | 468 | 80 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 436 | 60 |
| Clopidogrel | Clopidogrel Bisulfate | 427 | 48 |
| Clobetasol Propionate | Clobetasol Propionate | 425 | 87 |
| Folic Acid | Folic Acid | 419 | 94 |
| Fenofibrate | Fenofibrate,micronized | 414 | 44 |
| Mometasone Furoate | Mometasone Furoate | 410 | 58 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 388 | 74 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 372 | 47 |
| Azithromycin | Azithromycin | 368 | 252 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 347 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 48 |
| Jardiance | Empagliflozin | 327 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 324 | 87 |
| Finasteride | Finasteride | 287 | 38 |
| Furosemide | Furosemide | 281 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 281 | 85 |
| Propranolol Hcl | Propranolol Hcl | 259 | 28 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 253 | 126 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 244 | 220 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 237 | 51 |
| Januvia | Sitagliptin Phosphate | 231 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 221 | 161 |
| Farxiga | Dapagliflozin Propanediol | 220 | 26 |
| Vemlidy | Tenofovir Alafenamide | 211 | 19 |
| Procto-Med Hc | Hydrocortisone | 203 | 50 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 193 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 188 | 61 |
| Montelukast Sodium | Montelukast Sodium | 186 | 29 |
| Erythromycin | Erythromycin Base | 185 | 43 |
| Tradjenta | Linagliptin | 184 | 19 |
| Bepotastine Besilate | Bepotastine Besilate | 179 | 43 |
| Icosapent Ethyl | Icosapent Ethyl | 175 | 58 |
| Carvedilol | Carvedilol | 171 | 22 |
| Colchicine | Colchicine | 169 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 29 |
| Ketoconazole | Ketoconazole | 163 | 41 |
| Eliquis | Apixaban | 156 | 18 |
| Azelastine Hcl | Azelastine Hcl | 149 | 35 |
| Potassium Chloride | Potassium Chloride | 148 | 22 |
| Atenolol | Atenolol | 145 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 144 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 129 | 30 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 128 | 33 |
| Nexium | Esomeprazole Magnesium | 128 | 16 |
| Loperamide | Loperamide Hcl | 120 | 63 |
| Metformin Hcl | Metformin Hcl | 118 | 15 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 116 | 25 |
| Clonidine Hcl | Clonidine Hcl | 109 | 14 |
| Xarelto | Rivaroxaban | 107 | 13 |
| Dutasteride | Dutasteride | 102 | 12 |
| Linzess | Linaclotide | 102 | 13 |
| Prolia | Denosumab | 100 | 64 |
| Methimazole | Methimazole | 99 | 11 |
| Fluocinonide | Fluocinonide | 97 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 77 |
| Meloxicam | Meloxicam, Submicronized | 96 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 88 | 36 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 86 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 83 | 37 |
| Telmisartan | Telmisartan | 81 | suppressed |
| Lidocaine | Lidocaine | 78 | 22 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 77 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 11 |
| Nifedipine Er | Nifedipine | 76 | 11 |
| Latanoprost | Latanoprost | 74 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 72 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 72 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | suppressed |
| Sucralfate | Sucralfate | 71 | suppressed |
| Synthroid | Levothyroxine Sodium | 71 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 69 | 11 |
| Nitroglycerin | Nitroglycerin | 68 | 17 |
| Levofloxacin | Levofloxacin | 67 | 59 |
| Hydrocortisone | Hydrocortisone | 66 | 28 |
| Baclofen | Baclofen | 60 | 11 |
| Glipizide | Glipizide | 60 | suppressed |
| Lisinopril | Lisinopril | 60 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 59 | 29 |
| Tobramycin | Tobramycin | 55 | 32 |
| Niacin Er | Niacin | 54 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 44 | suppressed |
| Lubiprostone | Lubiprostone | 44 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 44 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 41 | suppressed |
| Entecavir | Entecavir | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Prednisone | Prednisone | 40 | 21 |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 39 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 39 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Glipizide Er | Glipizide | 37 | suppressed |
| Restasis | Cyclosporine | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Alphagan P | Brimonidine Tartrate | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Febuxostat | Febuxostat | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | 15 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | 17 |
| Benicar | Olmesartan Medoxomil | 30 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Bystolic | Nebivolol Hcl | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | suppressed |
| Acarbose | Acarbose | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Proctozone-Hc | Hydrocortisone | 23 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 22 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 14 | suppressed |
| Olanzapine Odt | Olanzapine | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Evista | Raloxifene Hcl | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,754.08 · 80 records | ABBVIE INC. | AREXVY, BREZTRI, CREON, EVENITY, FARXIGA, LINZESS, OTEZLA, REPATHA, SHINGRIX, VRAYLAR, VYALEV, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error